Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA. VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004
Medication labelWhy this: Advisory · dailymed-prescription
VIDAZA® is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). VIDAZA is indicated for the treatment of pediatric patients aged one month and older with newly diagnosed JMML.
- generic_name
- azacitidine
- product_names
- azacitidine
- ndc
- 59572-102, 59572-102-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en